1,024 transcripts
Page 6 of 52
bn7b
Earnings call transcript
NASDAQ
2023 Q4
6 Mar 24
Report on Form 10-K and quarterly report on Form 10-Q. The company's SEC filing are available on the Investors section of our website.These forward-looking
8jpf
Earnings call transcript
NASDAQ
2023 Q4
6 Mar 24
expressed or implied in these statements. These include risks and other factors outlined in our filings with the SEC, including our 10-K, which
4s
Earnings call transcript
NYSE
2024 Q1
6 Mar 24
, among others, matters that we've described in our Form 8-K filed with the SEC earlier today and other filings we make with the SEC. We disclaim any
c3h
Earnings call transcript
NASDAQ
2023 Q4
6 Mar 24
on the earnings press release as well as in the company's 2022 10-K, which was filed on March 16, 2023 with the SEC.
Additionally, the company may discuss
ni
Earnings call transcript
NYSE
2024 Q4
6 Mar 24
more fully in the company's press release and reports filed with the SEC, including the most recently filed Form 10-K or Form 10-Q.Any changes
1w2q
Earnings call transcript
NASDAQ
2023 Q4
6 Mar 24
Form 10-K for the year ended December 31, 2023. The company undertakes no obligation to publicly update or revise any forward-looking statements
k87g
Earnings call transcript
NASDAQ
2023 Q4
6 Mar 24
, including, without limitation, the company's Forms 20-F and 6-K, which identify specific factors that may cause actual results or events to differ
rb7
Earnings call transcript
NASDAQ
2023 Q4
6 Mar 24
-K and Form 10-Q or any updates at our current reports on Form 8-K filed with the U.S. Securities and Exchange Commission and InspireMD's press release
a8yu
Earnings call transcript
NASDAQ
2023 Q4
6 Mar 24
can find reconciliation tables to the most comparable GAAP figures in our press release and 10-K filed with the SEC today. Turning to our financial
fe
Earnings call transcript
NASDAQ
2023 Q4
6 Mar 24
and uncertainties affecting the company as described in the Risk Factors section and in other sections included in the company's annual report on Form 10-K filed
tu
Earnings call transcript
NYSE
2023 Q4
6 Mar 24
that could cause our actual results to differ materially from historical results and/or from our forecast, including those set forth in those Form 8-K
wr
Earnings call transcript
NYSE
2023 Q4
6 Mar 24
, in our Form 8-K dated March 6, 2024 and in the related presentation, each of which may be accessed from the Investor Relations page of the company's
a7p
Earnings call transcript
NASDAQ
2024 Q4
5 Mar 24
release, which may be found on the Investor Relations website at ir.crowdstrike.com or on our Form 8-K filed with the SEC today.
With that, I will now
q4e
Earnings call transcript
NYSE
2023 Q4
5 Mar 24
issued today as well as risks described in our annual report on Form 10-K, particularly in the section of these documents titled Risk Factors.Our
un
Earnings call transcript
NASDAQ
2023 Q4
5 Mar 24
and uncertainties described under the Risk section included in Plus Therapeutics' annual report on Form 10-K and quarterly reports on Form 10-Q filed
bcn
Earnings call transcript
NYSE
2024 Q4
5 Mar 24
2025 on a non-GAAP basis. Also, in addition to our press release and 8-K filing, the Overview page and Events and Presentations page in the Investors
fegl
Earnings call transcript
NASDAQ
2023 Q4
5 Mar 24
described in today's presentation, today's press release, APEI's Form 10-K for 2023, and the other SEC filings. The company undertakes no obligation
5n
Earnings call transcript
NYSE
2023 Q4
5 Mar 24
.
Before moving to our guidance for the year, I want to provide an update around our internal controls as previewed in our 8-K filing on February 6
37d8
Earnings call transcript
NYSE
2024 Q4
5 Mar 24
was posted today on our website and was filed today with the SEC on Form 8-K.
Also, please note that we use certain non-GAAP financial measures
b2
Earnings call transcript
NASDAQ
2023 Q4
5 Mar 24
with the Securities and Exchange Commission, including Form 10-K, 10-Q and 8-K. I will now turn the call over to our CEO, Dr. Scott Braunstein.
Thank